🔗 Share this article

While America undertakes sweeping revisions to its vaccine recommendations, an unexpected name appears in a surprising turn: Høeg, a Danish American physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 shots in the pandemic and has focused upon alleged deaths following COVID-19 immunization in her short time at the FDA.

Planned Changes to Pediatric Vaccine Schedule

Health officials were set to reveal radical revisions to the pediatric immunization program in December, synchronizing the US with Denmark’s national calendar, it is understood – a substantial departure that would place the US out of step with many the international standard with no evidence for improved outcomes. The announcement has been delayed until the coming year.

Instead of Vinay Prasad, Høeg is listed to present at the meeting. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the division this year.

A New Direction at the Agency

This interim role might represent a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad consolidate power at the agency – and it suggests a renewed priority upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for ending specific pediatric immunization guidelines in the US in order to be more in line with Denmark's approach, a nation with nationalized medicine and a number of inhabitants roughly the population of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on vaccines – typically the domain of Dr. Prasad, director of the FDA’s vaccine center – rather than pharmaceutical oversight.

Concerns Over Background

Høeg has no apparent track record in pharmaceutical research, approval processes or administrative roles, which has been standard for previous leaders of the biologics center. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since March.

“It seems she lacks to have the requisite experience” for running the CDER, stated Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in managing a sizeable institution. She has no expertise in pharmaceutical oversight.”

Previous heads of CBER would “understand laws and regulations and the underlying principles of pharmaceutical innovation”, said a former acting FDA commissioner. “Frankly, she doesn’t have the kind of background that former directors who headed the center have had.”

CDER has an vast workload at the agency, the former commissioner stated.

“Many people just pays attention on the novel medication approvals, but the generic program approves a multitude of generic drugs. There’s a biosimilars program, over-the-counter program and more, and all of those must be managed,” Dr. Woodcock noted. “The area you neglect, that is precisely what that I always told people is going to bite you.”

There is also, a substantial leadership component to the role, which supervises more than 5,000 staff members. “It’s a massive management job, if you perform it correctly,” Woodcock added.

Agency Reaction and Contentious Policies

In response to questions about Dr. Høeg's fitness for the role and whether this selection signifies more teamwork among agency officials on immunizations, a spokesperson said that the “questions are based on flawed assumptions”.

“Her resume aligns with the responsibilities of her role,” the spokesperson explained, noting the period Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and vaccine surveillance”.

As acting director, Dr. Høeg takes over the agency head's controversial expedited review system, a controversial one-day drug-approval program that apparently concerned her former heads. “How are these therapies being picked for this expedited pathway? Who makes the choices?” Dr. Howard questioned. “There is a lot of lack of transparency occurring at the agency right now.”

Broadly speaking, he stated, “the FDA looks to be trending towards less stringent oversight of most medications, with the exception of immunizations.”

Public Track Record on Immunizations

Regarding vaccines, Dr. Høeg has a more established, if concerning, past, critics said. She published a research paper using unverified volunteer-provided data to estimate the frequency of heart inflammation after Covid vaccination. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have modified findings to indicate Covid vaccinations are pose a greater threat than they are.

Among her “wish list” for the current federal leadership featured changing regulations for novel immunizations and halting “optional” immunizations, she said following the vote on a online show. At the FDA, Høeg has according to sources suggested preventing teenage boys from receiving Covid vaccines.

“She is an thorough ideologue who starts off with her conclusions and tailors the evidence to fit the data in a very deceptive, untruthful manner,” Howard argued.

Gaining Influence and a “Campaign of Retribution”

Høeg aligned with fellow dissenters, {like|